Gilberto Lopes, Chief of the Division of Medical Oncology at Sylvester Comprehensive Cancer Center, shared on X:
“Presidential Symposium at WCLC26: final OS from PAPILLON in 1L EGFR exon 20 insertion NSCLC.
Amivantamab + chemotherapy vs chemotherapy:
- Median OS 34.3 vs 27.9 mo
- HR 0.87 (95% CI 0.66–1.14)
- P=0.307
So the ITT OS result was not statistically significant.
The key context is crossover. Among chemotherapy-arm patients who discontinued because of progression, 76% (97/128) subsequently received amivantamab. That likely attenuated the observed ITT OS difference.
Prespecified crossover-adjusted IPCW analysis:
- Median OS 34.3 vs 22.1 mo
- HR 0.57 (95% CI 0.39–0.82)
- nominal P=0.003
PFS2:
- 28.3 vs 17.5 mo
- HR 0.59
My take: the ITT OS result is statistically negative and should be described that way. But heavy crossover, strong prior PFS benefit, favorable PFS2, and supportive adjusted OS analyses still support amivantamab + chemotherapy as a foundational 1L regimen.”
This also can be interesting:
7 Powerful Advances in the ASCO 2026 Guideline for Driver-Positive Stage IV NSCLC
